15 March 2017
Sofitel Legend Amsterdam The Grand
Avril Daly - CEO of Retina International and VP of EURORDIS – Rare Disease Europe
Avril Daly is the CEO of Retina International the global patient-led umbrella group dedicated to the promotion of research into Rare and Inherited as well as Age-related forms of retinal degenerative conditions. She previously held the position of CEO at Fighting Blindness Ireland.
She is the Vice President of EURORDIS (Rare Disease Europe) and chairperson of the Genetic and Rare Disorders Organisation (GRDO), the Irish National Alliance for Rare Diseases. In 2011 Avril was appointed by the minister for health to the steering committee working towards the publication of the Irish National Plan for Rare Diseases, (2014) and now sits on its oversight committee and represents the patient voice on the working group of the Clinical Programme for Rare Diseases at the Irish Health Service Executive (HSE). Avril was previously co-chair of the National Vision Coalition in Ireland.
Avril was a founding board member of the Medical Research Charities Group (MRCG) and, the Irish Platform for Patients’ Organisations, Science and Industry (IPPOSI).
Avril was diagnosed with the rare retinal condition Retinitis Pigmentosa in 1998.
Presentations – Gold Sponsors
Dr. Thomas Solbach - Principal and Member of the Management Board at PwC
Title: Precision Medicine – Potentials, Implications and Challenges ahead
Dr. Thomas Solbach is a Principal and Member of the Management Board at PwC Strategy& Germany. He supports major global pharmaceutical companies at the intersection of R&D and Commercial. Specifically, he focuses on the transformation of the pharma business model towards precision medicine / personalized healthcare, incl. corporate strategies, organizational models, game-changing capabilities (incl. real-world-evidence, partnering), and required changes to the existing go-to-market model.
Joost Kromhout, EnterNext
Analyst Panel – Change is coming: drug pricing, innovation and twitter!
Sam Fazeli, Senior Pharma Analyst and Head of EMEA at Bloomberg
Sam Fazeli is a senior analyst and the EMEA head of Bloomberg Intelligence, a dynamic platform for in-depth research available on the Bloomberg Professional service at BI <GO>. Mr. Fazeli specializes in European pharmaceuticals and biotechnology.
Mr. Fazeli brings with him over 15 years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC.
Prior to joining Bloomberg in 2010, Mr. Fazeli worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, Mr. Fazeli was a research scientist for seven years.
Mr. Fazeli has been ranked a top analyst by both the U.K. and Pan-European Extel surveys. He received a bachelor’s of science from Cardiff University, and a Ph.D. in pharmacology from the University of London.
Jan de Kerpel, Executive Director, Corporate Finance Life Science & Healthcare, Kempen & Co.
Jan de Kerpel, Executive Director Life Sciences, Corporate Finance
Dr Jan De Kerpel is a recognized biotech/healthcare business and finance expert with more than 20 years of experience in the fields of drug development, equity analysis and capital market growth financing. He currently serves as Executive Director Corporate Finance Life Science/Healthcare at Kempen&Co. Prior to Kempen, he was during one decade Senior Equity Analyst, Pharma & Biotech at KBC Securities, which earned him 3 times the Financial Times/Starmine “Best European Biotech analyst” award. He started his professional activities in drug development at Tibotec-Virco (now JNJ) and Devgen (now Syngenta).
Jan has a proven track record in successfully identifying investment opportunities to a continuously expanding international investor base and has been instrumental in raising close to €1 billion in IPOs and other equity financing for numerous Benelux biotech, medtech, health services and pharmaceutical companies. Until recently, Jan served as board member of FlandersBio and is an invited speaker on topics relating healthcare innovation, strategic development with financing.
Academically, Jan earned a master and PhD in life sciences (Univ Leuven), postgraduate in Business Administration (Univ Leuven) and an executive MBA (Vlerick Business School), complemented with corporate finance classes (Univ Brussels).
Stephanie Put, Healthcare Analyst, Degroof Petercam
Stéphanie graduated in 2009 from the University of Leuven as MSc in Biology, after which she started a PhD at the Rega Insitute for Medical Research in the field of immunology. After defending her PhD in 2013, she continued as Postdoctoral researcher for another year. In 2014, she started as investor relations officer at Bone Therapeutics, where she was involved in the IPO of the company. In 2016, she became sell-side analyst at Bank Degroof Petercam, specializing in healthcare.
Michael Rice, Founding Partner, LifeSci Advisors
Michael Rice has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at Think Equity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.
Michaël Vlemmix, Sell-side Financial Analyst, Biotech & Healthcare, KBC Securities
Michaël Vlemmix, MSc – Sell-side Financial Analyst Biotech/Healthcare
Michaël joined the research team of KBC Securities in 2016 to focus on the Biotech/Healthcare sector. He was active for 3 years in the start-up of a Medical Devices spin-off company of the University of Antwerp. He graduated as a Bio-Engineer at the University of Ghent and Antwerp, specialized in Cell and Gene Biotechnology (cancer genetics) and obtained an additional Master in Management at the Antwerp Management School.